Author: Junell Harrington

HCP & Pharma Online Congress Engagement: ASCO and ESMO

The American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) annual congresses are some of the most prestigious and well attended by healthcare professionals (HCPs) in oncology. Although the associations that run the meetings are based in the United States and Europe, respectively, they draw attendees from all around the world. Congress meetings such as these not only provide an opportunity for HCPs to connect and engage with the pharmaceutical companies who sponsor, present and attended these congresses, but also help in starting global conversations between HCP peers online. Using CREATION Pinpoint we tracked...

Read More

HCPs show growing excitement about Haemophilia game changer

In the UK, around 6,000 people have been diagnosed with haemophilia, with type A being the most common. Globally, it is estimated that 1 in 5,000 and 1 in 30,000 men have haemophilia A and B respectively. As in other rare disease areas, we are seeing healthcare professionals (HCPs) with an interest in haemophilia heading online to connect with other specialists – both in their own markets and globally – to discuss the therapy area, regulatory changes and the evolving treatment landscape. In particular, there is growing excitement amongst HCPs about the potential of new treatments not only to...

Read More

What HCPs in the UK say about Chronic Kidney Disease

This article was written and researched by Adam Doggett & Junell Harrington, Research Analysts at CREATION The Chronic Kidney Disease (CKD) model estimates that 6.1% of over-16-year-olds in the United Kingdom are living with stage 3-5 CKD. CKD is characterised by damage to the kidneys resulting in reduced long-term functionality. The disease is often associated with other conditions, with conversations held between healthcare professionals (HCPs) online reflecting this. Twitter provides valuable insights into HCP discussions; here we dive into the data to identify the topics discussed among HCPs in the UK. HCPs’ key topics of discussion Discussions amongst HCPs about CKD...

Read More

What HCPs say about access to high-priced Hepatitis C drugs

This article was written and researched by Jamie Doggett and Junell Harrington, Research Analysts at CREATION In 2013 and 2014 Gilead Sciences released two new drugs listed for the treatment of Hepatitis C (HCV): Harvoni (ledipasvir–sofosbuvir) and Sovaldi (sofosbuvir). This brought to the forefront the contention between expensive drugs that are highly effective and the lack of affordability for both individuals and healthcare providers such as Medicaid in the US and NHS England. This was further highlighted by Gilead’s latest HCV drug Epclusa (sofosbuvir-velpatasvir) released last month, which treats all strains of HCV. This combined with the rise of sensational...

Read More

Twitter

Categories

The HCP insights eJournal for leaders in healthcare  Subscribe